Abstract
Over the past several decades, plant-derived products (phytochemicals) have been suggested to possess immense therapeutic potential. Among these phytochemicals, different flavonoids have been reported for their potent anticancer activity. To exhibit their anticancer potential, these flavonoids modulate different signaling pathways. Among these pathways, the mammalian target of rapamycin (mTOR) and associated phosphatidyl-inositol 3-kinase (PI3K)/protein kinase B (Akt) signaling cascade have been reported as a pivotal modulator of cell survival, proliferation, and death/apoptosis. Hence, targeting this cascade could be an ideal strategy to alleviate apoptosis and inhibit proliferation in different forms of cancer. The targeting of PI3K/Akt/mTOR by flavonoids have been well documented in the scientific literature. In the current study, we have studied the anticancer potential of various flavonoids, especially flavones, flavonols, and isoflavones that include apigenin, luteolin, baicalein, tangeretin, epigallocatechin- 3-gallate, genistein, and daidzein especially dealing with mTOR targeting.
Keywords: Apigenin, baicalein , cancer prevention, daidzein , epigallocatechin-3-gallate, flavonoids, genistein, luteolin, tangeretin, mTOR.
Current Medicinal Chemistry
Title:mTOR Targeted Cancer Chemoprevention by Flavonoids
Volume: 28 Issue: 39
Author(s): Badar ul Islam, Mohd Shahnawaz Khan, Fohad Mabood Husain, Md Tabish Rehman, Torki A. Zughaibi, Adel M. Abuzenadah, Maryam Urooj, Mohammad Amjad Kamal and Shams Tabrez*
Affiliation:
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah,Saudi Arabia
Keywords: Apigenin, baicalein , cancer prevention, daidzein , epigallocatechin-3-gallate, flavonoids, genistein, luteolin, tangeretin, mTOR.
Abstract: Over the past several decades, plant-derived products (phytochemicals) have been suggested to possess immense therapeutic potential. Among these phytochemicals, different flavonoids have been reported for their potent anticancer activity. To exhibit their anticancer potential, these flavonoids modulate different signaling pathways. Among these pathways, the mammalian target of rapamycin (mTOR) and associated phosphatidyl-inositol 3-kinase (PI3K)/protein kinase B (Akt) signaling cascade have been reported as a pivotal modulator of cell survival, proliferation, and death/apoptosis. Hence, targeting this cascade could be an ideal strategy to alleviate apoptosis and inhibit proliferation in different forms of cancer. The targeting of PI3K/Akt/mTOR by flavonoids have been well documented in the scientific literature. In the current study, we have studied the anticancer potential of various flavonoids, especially flavones, flavonols, and isoflavones that include apigenin, luteolin, baicalein, tangeretin, epigallocatechin- 3-gallate, genistein, and daidzein especially dealing with mTOR targeting.
Export Options
About this article
Cite this article as:
Badar ul Islam , Khan Shahnawaz Mohd , Husain Mabood Fohad , Rehman Tabish Md , Zughaibi A. Torki , Abuzenadah M. Adel , Urooj Maryam , Kamal Amjad Mohammad and Tabrez Shams *, mTOR Targeted Cancer Chemoprevention by Flavonoids, Current Medicinal Chemistry 2021; 28 (39) . https://dx.doi.org/10.2174/0929867327666201109122025
DOI https://dx.doi.org/10.2174/0929867327666201109122025 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Dynamics in Esophageal Adenocarcinoma: Who’s in Control?
Current Cancer Drug Targets Molecular Targeting of ERKs/RSK2 Signaling in Cancers
Current Pharmaceutical Design Pathways Related to the Anti-Cancer Effects of Metabolites Derived from Cerrado Biome Native Plants: An Update and Bioinformatics Analysis on Oral Squamous Cell Carcinoma
Protein & Peptide Letters The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants
Current Pharmaceutical Design Editorial (Thematic Issue: Anticancer Natural Compounds: Molecular Mechanisms and Functions. Part I)
Current Genomics Electroporation Gene Therapy Preclinical and Clinical Trials for Melanoma
Current Gene Therapy Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Therapeutic Strategy of Advanced Hepatocellular Carcinoma by Using Combined Intra-Arterial Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Gene Delivery for Cancer Therapy
Current Drug Delivery Biomarkers for Early Detection of Liver Cancer: Focus on Clinical Evaluation
Protein & Peptide Letters Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy: The First Approved Gene-Based Medicines, Molecular Mechanisms and Clinical Indications
Current Molecular Pharmacology MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets Proteasome Regulators: Activators and Inhibitors
Current Medicinal Chemistry Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design MicroRNA-34b Inhibits Pancreatic Cancer Metastasis Through Repressing Smad3
Current Molecular Medicine Patent Selections
Recent Patents on Biomarkers